04:43 PM EDT, 06/14/2024 (MT Newswires) -- Amgen ( AMGN ) said late Friday the US Food and Drug Administration has cleared Blincyto to treat adults and children one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, an aggressive type of blood cancer.

The FDA approval, which is the third indication for Blincyto, covers people with the disease in the consolidation phase, regardless of measurable residual disease status, the company said.